Cello Health (CLL)

Sector:

Health Care

Index:

FTSE AIM All-Share

 110.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 148.50
  • 52 Week Low: 101.00
  • Currency: UK Pounds
  • Shares Issued: 106.23m
  • Volume: 56,952
  • Market Cap: £116.85m
  • RiskGrade: 258

Wednesday broker round-up UPDATE

Date: Wednesday 25 Sep 2013

LONDON (ShareCast) - Amec: JP Morgan reduces target price from 1301p to 1243p and stays with its neutral rating.

Amlin: UBS ups target price from 400p to 450p upgrading from neutral to buy.

BAE Systems: UBS takes target price from 450p to 490p and maintains a buy recommendation.

BHP Billiton: Alphavalue shifts target price from 2016.10p to 2020.90p upgrading from reduce to add.

Brown (N) Group: UBS increases target price from 445p to 565p and retains a neutral rating.

Carnival: UBS cuts target price from 2400p to 2200p reiterating its neutral rating. Morgan Stanley downgrades to underweight with a target price of 2000p. Numis downgrades to hold with a target price of 2250p.

Clinigen: Investec places both its target price (prev.: 313p) and its hold recommendation unchanged.

Close Brothers: UBS raises target price from 1050p to 1250p and maintains a neutral rating. JP Morgan ups target price from 1134p to 1212p keeping an overweight rating. Numis raises target price from 875p to 1015p, while downgrading to reduce.

Daily Mail & General Trust: Westhouse Securities increases target price from 695p to 744p, while its neutral rating remains unaltered. Canaccord Genuity ups target price from 721p to 751p and keeps its hold recommendation.

Dialight: N+1 Singer reduces target price from 1617p to 1370p with a buy recommendation.

Entertainment One: Investec takes target price from 225p to 270p and stays with its buy recommendation.

GKN: UBS takes target price from 350p to 400p and stays with its buy recommendation. Credit Suisse increases target price from 355p to 395p and reiterates its outperform rating.

Greencore Group: Numis upgrades from hold to add.

ICAP: Numis downgrades to sell with a target price of 292p.

Menzies (John): JP Morgan takes target price from 852p to 884p and keeps an overweight rating.

Millennium & Copthorne: Exane raises target price from 510p to 530p, while downgrading from neutral to underperform.

Punch Taverns: Numis downgrades from buy to hold with a target price of 15p. Panmure Gordon downgrades from hold to sell with a target price of 7p.

PZ Cussons: Panmure Gordon takes target price from 430p to 445p and keeps a buy recommendation.

Smith & Nephew: Credit Suisse moves target price from 750p to 775p, while its neutral rating is kept.

Smith News: JP Morgan takes target price from 213p to 236p retaining an overweight rating.

Smiths Group: UBS ups target price from 1400p to 1450p, while downgrading from buy to neutral. Investec increases target price from 1590p to 1640p and keeps a buy recommendation.

SSE: Credit Suisse raises target price from 1650p to 1700p and leaves its outperform rating unchanged.

STV Group: Liberum Capital moves target price from 360p to 370p retaining its buy recommendation.

Telecity Group: Jefferies upgrades to buy with a target price of 1020p.

Tesco: JP Morgan cuts target price from 390p to 350p and downgrades from neutral to underweight.

UK Mail Group: Investec ups target price from 600p to 630p reiterating a buy recommendation.

Zambeef: Panmure Gordon reduces target price from 55p to 38p downgrading from buy to hold.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Cello Health Market Data

Currency UK Pounds
Share Price 110.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 148.50
52 Week Low 101.00
Volume 56,952
Shares Issued 106.23m
Market Cap £116.85m
RiskGrade 258

Cello Health Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
64.69% below the market average64.69% below the market average64.69% below the market average64.69% below the market average64.69% below the market average
83.78% above the sector average83.78% above the sector average83.78% above the sector average83.78% above the sector average83.78% above the sector average
Price Trend
21.22% above the market average21.22% above the market average21.22% above the market average21.22% above the market average21.22% above the market average
12.2% below the sector average12.2% below the sector average12.2% below the sector average12.2% below the sector average12.2% below the sector average
Income
26.26% below the market average26.26% below the market average26.26% below the market average26.26% below the market average26.26% below the market average
86.67% above the sector average86.67% above the sector average86.67% above the sector average86.67% above the sector average86.67% above the sector average
Growth
39.24% below the market average39.24% below the market average39.24% below the market average39.24% below the market average39.24% below the market average
38.89% below the sector average38.89% below the sector average38.89% below the sector average38.89% below the sector average38.89% below the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 2
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Cello Health Dividends

  Latest Previous
  Interim Final
Ex-Div 03-Oct-19 25-Apr-19
Paid 01-Nov-19 24-May-19
Amount 1.15p 2.75p

Trades for 09-Apr-2020

Time Volume / Share Price
16:31 25,000 @ 110.00p
16:06 25,000 @ 110.00p
15:57 608 @ 111.64p
15:45 1,897 @ 112.00p
14:39 4,450 @ 109.06p

Cello Health Key Personnel

CEO Mark Scott

Top of Page